Clinical Research Directory
Browse clinical research sites, groups, and studies.
The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Venous Thromboembolism (DANNOAC-VTE)
Sponsor: Herlev and Gentofte Hospital
Summary
No randomized head-to-head comparison between the individual Non-vitamin K Antagonist Oral Anticoagulants (NOAC) exists. The DANNOAC-VTE study is a nationwide cluster randomized cross-over study comparing efficacy and safety of the four NOACs, edoxaban, apixaban, rivaroxaban and dabigatran for oral anticoagulation in venous thromboembolism across Danish hospitals.
Official title: The Danish Non-vitamin K Antagonist Oral Anticoagulation Study. A Cluster Randomized Study Comparing Safety and Efficacy of Edoxaban, Apixaban, Rivaroxaban and Dabigatran for Oral Anticoagulation in Patients With Venous Thromboembolism.
Key Details
Gender
All
Age Range
Any - Any
Study Type
INTERVENTIONAL
Enrollment
5000
Start Date
2023-04-01
Completion Date
2029-03-31
Last Updated
2025-05-15
Healthy Volunteers
No
Conditions
Interventions
Dabigatran Etexilate Oral Capsule
After cluster randomization, the cluster will use dabigatran to all their patients with venous thromboembolism when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time. It is the clusters and not the patient that are randomized.
Rivaroxaban Oral Tablet
After cluster randomization, the cluster will use rivaroxaban to all their patients with venous thromboembolism when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time. It is the clusters and not the patient that are randomized.
Edoxaban Oral Tablet
After cluster randomization, the cluster will use edoxaban to all their patients with venous thromboembolism when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time. It is the clusters and not the patient that are randomized.
Apixaban Oral Tablet
After cluster randomization, the cluster will use apixaban to all their patients with venous thromboembolism when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time. It is the clusters and not the patient that are randomized.
Locations (26)
Aarhus University Hospital
Aarhus, Denmark
Bispebjerg and Frederiksberg Hospital
Copenhagen, Denmark
Bispebjerg Hospital
Copenhagen NV, Denmark
Amager Hospital
Copenhagen S, Denmark
Rigshospitalet
Copenhagen Ø, Denmark
Esbjerg Hospital
Esbjerg, Denmark
Nordsjællands Hospital - Frederiksund
Frederikssund, Denmark
Herlev Gentofte Hospital
Gentofte Municipality, Denmark
Glostrup Hospital - Department of Emergency Medicine
Glostrup Municipality, Denmark
Glostrup Hospital - Department of Medicine / Cardiology
Glostrup Municipality, Denmark
Glostrup Hospital - Department of Neurology
Glostrup Municipality, Denmark
Herlev-Gentofte Hospital - Department of Medicine
Herlev, Denmark
Nordsjællands Hospital - Hillerød
Hillerød, Denmark
Hjørring Hospital
Hjørring, Denmark
Holbæk Hospital
Holbæk, Denmark
Hvidovre Hospital
Hvidovre, Denmark
Næstved Hospital
Næstved, Denmark
Odense University Hospital - Department of Cardiology
Odense, Denmark
Odense University Hospital - Department of Emergency Medicine
Odense, Denmark
Odense University Hospital - Department of Geriatrics
Odense, Denmark
Zealand University Hospital - Department of Neurology
Roskilde, Denmark
Zealand University Hospital Roskilde - Department of Cardiology
Roskilde, Denmark
Bornhoms Hospital
Rønne, Denmark
Slagelse Hospital
Slagelse, Denmark
Odense University Hospital Svendborg
Svendborg, Denmark
Vejle Hospital
Vejle, Denmark